Sound Bioventures backs Breye Therapeutics in €67.5 million Series A round

• Breye Therapeutics, a clinical-stage biotech developing oral drugs for early retinal disease, closed a EUR 67.5 million oversubscribed Series A.
• Sound Bioventures Management AB participated alongside co-leads Mission BioCapital and Novo Holdings, expanding funding for Breye’s development plans.
• Proceeds target a randomized Phase 2 trial of danegaptide in non-proliferative diabetic retinopathy, with study start planned for 2027.
• Capital also supports pipeline work in retinal disease, including an oral P2X7 receptor antagonist program for intermediate age-related macular degeneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sound Bioventures Management AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.